Tharun Kotaru
Internal Medicine · Omaha, NENPI 1033780648
Payments from drug & device makers
Across 62 payments — averaging $37.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- United Therapeutics Corporation$173
- W. L. Gore & Associates, Inc.$167
- Abiomed$139
- Amgen$68
- Grifols USA, LLC$67
- plus $482 from 14 others
What the payments were for
- Food & beverage$2,29599%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $1,217 |
| United Therapeutics Corporation | 2 | $173 |
| W. L. Gore & Associates, Inc. | 1 | $167 |
| Abiomed | 2 | $139 |
| Amgen | 4 | $68 |
| Grifols USA, LLC | 2 | $67 |
| Jazz Pharmaceuticals Inc. | 3 | $64 |
| Boehringer Ingelheim | 3 | $60 |
| Insmed, Inc. | 3 | $59 |
| Ferring Pharmaceuticals Inc. | 1 | $55 |
| Sanofi | 2 | $49 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Merck | 1 | $32 |
| Ambu Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $21 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| UCB, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,314 in reported general payments places this provider in the 85th percentile of 570 internal medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,116 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Omaha
- Michael DunnOmaha$7.9M
- Joel MichalskiOmaha$1.6M
- Ariana BauerOmaha$1.5M
- David CrockettOmaha$821K
- Bryant EnglandOmaha$637K
- Adam BurdorfOmaha$313K
- Brian BoerOmaha$142K
- David JasperOmaha$128K
- Andrew RorieOmaha$61K
- Mohamed AhmedOmaha$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.